Lance D. Miller, Ph.D.Wake Forest School of Medicine

Lance D. Miller, Ph.D.

Core Director,
Associate Professor,

Clinical Interests

Cancer Cell Biology, Cancer Genetics, Breast Cancer

Contact Information

Academic: 336-716-6017 | Department: 336-716-6017


Media Medical Expert »

Education & Training

  • B.S., University of North Carolina-Chapel Hill, 1992
  • M.S., East Carolina University, 1995
  • Ph.D., University of North Carolina-Chapel Hill, 2001
Lance D. Miller, Ph.D.

Lance D. Miller, Ph.D.

Core Director, Comprehensive Cancer Center
Associate Professor, Cancer Biology
Office of Women in Medicine and Science

Research Interests

Breast Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Oligonucleotide Array Sequence Analysis; Iron
More »

Contact Information

Academic: 336-716-6017 | Department: 336-716-6017


Media Medical Expert »

Recent Publications

EGFR and HER2 signaling in breast cancer brain metastasis. Sirkisoon SR, Carpenter RL, Rimkus T, Miller L, Metheny-Barlow L, Lo HW.. Front Biosci (Elite Ed). 2016;8():245-263.

ERRalpha is a marker of tamoxifen response and survival in triple-negative breast cancer. Manna S, Bostner J, Sun Y, Miller LD, Alayev A, Schwartz NS, Lager E, Fornander T, Nordenskjold B, Yu JJ, Stal O, Holz MK.. Clin Cancer Res. 2016;22(6):1421-1431.

Yin Yang 1 promotes mTORC2-mediated AKT phosphorylation. Zhang Q, Wan M, Shi J, Horita DA, Miller LD, Kute TE, Kridel SJ, Kulik G, Sui G.. J Mol Cell Biol. 2016;8(3):232-243.

Prognostic molecular subtypes of low-grade cancer of the appendix. Levine EA, Votanopoulos KI, Qasem SA, Philip J, Cummins KA, Chou JW, Ruiz J, D'Agostino R, Shen P, Miller LD.. J Am Coll Surg. 2016;222(4):493-503.

Disentangling the relationship between tumor genetic programs and immune responsiveness. Bedognetti D, Hendrickx W, Ceccarelli M, Miller LD, Seliger B.. Curr Opin Immunol. 2016;39():150-158.

Effects of pubertal exposure to dietary soy on estrogen receptor activity in the breast of cynomolgus macaques. Dewi FN, Wood CE, Willson CJ, Register TC, Lees CJ, Howard TD, Huang Z, Murphy SK, Tooze JA, Chou JW, Miller LD, Cline JM.. Cancer Prev Res (Phila Pa). 2016;9(5):385-395.

Immunogenic subtypes of breast cancer delineated by gene classifiers of immune responsiveness. Miller LD, Chou JA, Black MA, Print C, Chifman J, Alistar A, Putti T, Zhou X, Bedognetti D, Hendrickx W, Pullikuth A, Rennhack J, Andrechek ER, Demaria S, Wang E, Marincola FM.. Cancer Immunol Res. 2016;4(7):600-610.

Gene expression signatures of effector immune cell abundance are significantly associated with recurrence risk in colon cancer [abstract]. Alistar AT, Chifman J, D'Agostino R Jr, Miller LD.. Cancer Immunol Res. 2016;4(1 Suppl):A011.

Gene variability between perineural-positive and perineural-negative squamous cell skin cancers. Mays AC, Chou J, Craddock AL, Miller L, Browne JD.. Anticancer Res. 2016;36(8):4007-4011.

Hepcidin regulation in prostate and its disruption in prostate cancer. Tesfay L, Clausen KA, Kim JW, Hegde P, Wang X, Miller LD, Deng Z, Blanchette N, Arvedson T, Miranti CK, Babitt JL, Lin HY, Peehl DM, Torti FM, Torti SV.. Cancer Res. 2015;75(11):2254-2263.

A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer. Cowherd S, Miller LD, Melin SA, Akman S, Isom S, Cole J, Pullikuth A, Lawrence JA.. Cancer Biol Ther. 2015;16(5):678-683.

Systems biology approach to studying proliferation-dependent prognostic subnetworks in breast cancer. Song Q, Wang H, Bao J, Pullikuth AK, Li KC, Miller LD, Zhou X.. Sci Rep. 2015;5():12981.

Prognostic and predictive immune gene signatures in breast cancer. Bedognetti D, Hendrickx W, Marincola FM, Miller LD.. Curr Opin Oncol. 2015;27(6):433-444.

Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design. Holmes JA, Paulsson AK, Page BR, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD.. J Neurooncol. 2015;124(3):447-453.

Molecular subtyping in advanced non-small cell lung cancer, a minimally invasive strategy with small volume fine needle aspirates [abstract]. Hansen K, Miller L, Dotson T, Bellinger C, Parks G, Cappellari J, Clark H, Howard C, Bolemon B, Petty WJ, Craddock L, Ruiz J.. J Thorac Oncol. 2015;10(9 Suppl 2):S701.

IRP2 regulates breast tumor growth. Wang W, Deng Z, Hatcher H, Miller LD, Di X, Tesfay L, Sui G, D'Agostino RB Jr, Torti FM, Torti SV.. Cancer Res. 2014;74(2):497-507.

Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. Paulsson AK, Holmes JA, Peiffer AM, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD.. J Neurooncol. 2014;119(2):429-435.

A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL.. Clin Cancer Res. 2014;20(20):5255-5264.

DEAD-box helicase DP103 defines metastatic potential of human breast cancers. Shin EM, Hay HS, Lee MH, Goh JN, Tan TZ, Sen YP, Lim SW, Yousef EM, Ong HT, Thike AA, Kong X, Wu Z, Mendoz E, Sun W, Salto-Tellez M, Lim CT, Lobie PE, Lim YP, Yap CT, Zeng Q, Sethi G, Lee MB, Tan P, Goh BC, Miller LD, Thiery JP, Zhu T, Gaboury L,.. J Clin Invest. 2014;124(9):3807-3824.

Genomic predictors of infield and marginal failure for glioblastoma treated with concurrent radiation therapy and temozolomide: a step towards personalized radiation fields? [abstract]. Holmes JA, Paulsson A, Peiffer AM, Miller LD, Xu J, Hinson WH, Lesser GJ, Tatter SB, Debinski W, Chan MD.. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 1):S291-S292.

Dual roles for immune metagenes in breast cancer prognosis and therapy prediction. Alistar A, Chou JW, Nagalla S, Black MA, D'Agostino R Jr, Miller LD.. Genome Med. 2014;6(10):80.

Functional presence of M2 macrophage markers in GBM tumor cells [abstract]. Debinski W, Rodriguez A, Gibo D, Tatter SB, Mott R, Lively M, Miller L, Seals DF.. Neuro Oncol. 2014;16(Suppl 3):.

Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Oikawa T, Kamiya A, Zeniya M, Chikada H, Hyuck AD, Yamazaki Y, Wauthier E, Tajiri H, Miller LD, Wang XW, Reid LM, Nakauchi H.. Hepatology. 2013;57(4):1469-1483.

Irp2 regulates tumor growth in breast cancer [abstract]. Wang W, Deng ZY, Hatcher H, Miller L, Di XM, Tesfay L, D'Agostino RB Jr, Torti S, Torti F.. Am J Hematol. 2013;88(5):E15.

Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer. Maglic D, Zhu S, Fry EA, Taneja P, Kai F, Kendig RD, Sugiyama T, Miller LD, Willingham MC, Inoue K.. Oncogene. 2013;32(35):4120-4129.

Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Nagalla S, Chou JW, Willingham MC, Ruiz J, Vaughn JP, Dubey P, Lash TL, Hamilton-Dutoit SJ, Bergh J, Sotiriou C, Black MA, Miller LD.. Genome Biol. 2013;14(4):R34.

The regulation of SOX7 and its tumor suppressive role in breast cancer. Stovall DB, Wan M, Miller LD, Cao P, Maglic D, Zhang Q, Stampfer MR, Liu W, Xu J, Sui G.. Am J Pathol. 2013;183(5):1645-1653.

Fractionated whole brain irradiation modulates Homer1a expression in a brain region specific manner [abstract]. Moore E, Kooshki M, Miller L, Robbins M [deceased].. Cancer Res. 2013;73(8 Suppl 1):A78.

YB-1, the E2F pathway, and regulation of tumor cell growth. Lasham A, Samuel W, Cao H, Patel R, Mehta R, Stern JL, Reid G, Woolley AG, Miller LD, Black MA, Shelling AN, Print CG, Braithwaite AW.. J Natl Cancer Inst. 2012;104(2):133-146.

RAS mutations and oncogenesis: not all RAS mutations are created equally. Miller MS, Miller LD.. Front Genet. 2012;2():100.

Yin Yang 1 contains G-quadruplex structures in its promoter and 5'-UTR and its expression is modulated by G4 resolvase 1. Huang W, Smaldino PJ, Zhang Q, Miller LD, Cao P, Stadelman K, Wan M, Giri B, Lei M, Nagamine Y, Vaughn JP, Akman SA, Sui G.. Nucleic Acids Res. 2012;40(3):1033-1049.

Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27. Wan M, Huang W, Kute TE, Miller LD, Zhang Q, Hatcher H, Wang J, Stovall DB, Russell GB, Cao PD, Deng Z, Wang W, Zhang Q, Lei M, Torti SV, Akman SA, Sui G.. Am J Pathol. 2012;180(5):2120-2133.

Strategies to defeat ketamine-induced neonatal brain injury. Turner CP, Gutierrez S, Liu C, Miller L, Chou J, Finucane B, Carnes A, Kim J, Shing E, Haddad T, Phillips A.. Neuroscience. 2012;210():384-392.

Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. Caldon CE, Sergio CM, Kang J, Muthukaruppan A, Boersma MN, Stone A, Barraclough J, Lee CS, Black MA, Miller LD, Gee JM, Nicholson RI, Sutherland RL, Print CG, Musgrove EA.. Mol Cancer Ther. 2012;11(7):1488-1499.

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Prat A, Parker JS, Fan C, Cheang MC, Miller LD, Bergh J, Chia SK, Bernard PS, Nielsen TO, Ellis MJ, Carey LA, Perou CM.. Ann Oncol. 2012;23(11):2866-2873.

JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. Lee YF, Miller LD, Chan XB, Black MA, Pang B, Ong CW, Salto-Tellez M, Liu ET, Desai KV.. Breast Cancer Res. 2012;14(3):R85.

Molecular and genetic features of highly migratory glioblastoma cells [abstract]. Lema Tome CM, Miller LD, Debinski W.. Neuro Oncol. 2012;14(Suppl 6):162.

Genomic profiles specific to patient ethnicity in lung adenocarcinoma. Broet P, Dalmasso C, Tan EH, Alifano M, Zhang S, Wu J, Lee MH, Regnard J-F, Lim D, Miller LD, et al.. Clin Cancer Res. 2011;17(11):3542-3550.

Microarray gene expression patterns recapitulated on a clinically tractable diagnostic platform using breast and lung cancer formalin-fixed paraffin-embedded tissues [abstract]. Ruiz J, Chou J, Geisinger KR, Schoppe CH, Miller AA, Willingham MC, Petty WJ, Bolemon BH, Miller LD.. J Clin Oncol. 2011;29(Suppl):e21027.

Use of spermatozoal mRNA profiles to study genes affected by pesticide exposure in humans [abstract]. Hou L, Arcury T, Quandt S, Miller L, Howard T, Grzywacz J, Miller J, Yalcinkaya TM.. Reprod Sci. 2011;18(4 Suppl):175A.

Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer. Soon WW, Miller LD, Black MA, Dalmasso C, Chan XB, Pang B, Ong CW, Salto-Tellez M, Desai KV, Liu ET.. EMBO Mol Med. 2011;3(8):451-464.

SOSTDC1 differentially modulates Smad and beta-catenin activation and is down-regulated in breast cancer. Clausen KA, Blish KR, Birse CE, Triplette MA, Kute TE, Russell GB, D'Agostino RB Jr, Miller LD, Torti FM, Torti SV.. Breast Cancer Res Treat. 2011;129(3):737-746.

An iron regulatory gene signature predicts outcome in breast cancer. Miller LD, Coffman LG, Chou JW, Black MA, Bergh J, D'Agostino R Jr, Torti SV, Torti FM.. Cancer Res. 2011;71(21):6728-6737.

Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma. Kang J, Qian PX, Pandey V, Perry JK, Miller LD, Liu ET, Zhu T, Liu DX, Lobie PE.. Oncogene. 2010;29(22):3228-3240.

Ferroportin and iron regulation in breast cancer progression and prognosis. Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV, Torti FM.. Sci Transl Med. 2010;2(43):43ra56.

Neurotensin receptor 1 determines the outcome of non-small cell lung cancer. Alifano M, Souaze F, Dupouy S, Camilleri-Broet S, Younes M, Ahmed-Zaid S-M, Takahashi T, Cancellieri A, Damiani S, Miller LD, et al.. Clin Cancer Res. 2010;16(17):4401-4410.

The role of oestrogen signalling in breast cancer [abstract]. Muthukaruppan A, Michael BA, Miller LD, Tamada Y, Allen TM, Woad KJ, Wang Y, Crampin EJ, Shelling AN, Print CG.. Ann Oncol. 2010;21(Suppl 4):54-55.

Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. Kannan N, Kang J, Kong X, Tang J, Perry JK, Mohankumar KM, Miller LD, Liu ET, Mertani HC, Zhu T, et al.. Neoplasia. 2010;12(12):1041-1053.

Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Landen CN Jr, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, et al.. Mol Cancer Ther. 2010;9(12):3186-3199.

A novel prognostic transcriptional signature for early stage non-small cell lung cancer [abstract]. Ruiz J, Miller AA, Petty WJ, Chou JW, Miller LD.. J Thorac Oncol. 2010;5(12 Suppl 7):S505.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Associate Professor, Cancer Biology

Clinical Interests

Cancer Cell Biology, Cancer Genetics, Breast Cancer
Lance D. Miller, Ph.D.

Lance D. Miller, Ph.D.

Core Director, Comprehensive Cancer Center
Associate Professor, Cancer Biology
Office of Women in Medicine and Science

Quick Reference

Request an Appointment
New Patients


Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Comprehensive Cancer Centers National Designation is RenewedMagnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.